Efficacy of Equmet (Vildagliptin/Metformin) and Twymeeg (Imeglimin) With Stable Arteriosclerosis for Diabetic Elderly

Bando H, Ogawa T, Iwatsuki N, Okada M and Sakamoto K

Published on: 2024-05-09

Abstract

The case is 86-year-old male with type 2 diabetes (T2D), dyslipidemia and cerebral arteriosclerosis. His prescription included oral hypoglycemic agents (OHAs), atorvastatin and cilostazol. His physique showed BMI 20.9 kg/m², and ankle brachial index (ABI) was 1.14/1.19 by plethysmography. Brain MRI and MRA showed brain atrophy and ventricular enlargement to some extent, and slightly general atherosclerotic changes. HbA1c was elevated to 7.8% in January 2023, and then imeglimin (Twymeeg) and vildagliptin/metformin (EquMet) were initiated. HbA1c decreased to 7.1%, followed by 6.7% for several months. The results suggest satisfactory clinical efficacy of EquMet and Twymeeg for glucose variability of T2D.